1. Physiologic vs Chronologic Age

2. Learning Objectives

3. Clinical Scenario

7. Subgroup Analysis Cisplatin + Pemetrexed vs Cisplatin + Gemcitabine in Non-Squamous NSCLC

8. Pemetrexed Maintenance in Older Patients With Non-Squamous NSCLC

9. Frontline nab-Paclitaxel for Advanced NSCLC in Older Patients

10. Subgroup Analysis Frontline Bevacizumab in Older Patients With Non-Squamous NSCLC

11. SQUIRE Subgroup Analysis of Gemcitabine/Cisplatin ± Necitumumab

12. Erlotinib in Older Patients With NSCLC

13. Gefitinib in Older Patients With EGFR-Mutated NSCLC

14. Retrospective Analysis of First-Line Gefitinib in Patients ≥ 70 years with EGFR-Mutated NSCLC

15. LUX-Lung 3 Afatinib vs Cisplatin + Pemetrexed in Metastatic NSCLC

16. PROFILE 1014 Crizotinib vs Chemotherapy in ALK-Positive NSCLC

17. Conclusions and Final Thoughts

18. Abbreviations